TRimetazidine for acUte on Chronic Liver Failure STudy (TRUST)
A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure
Sponsor: Martin Pharmaceuticals
Suspended
Lack of enrollment
This PHASE1 trial investigates Acute-On-Chronic Liver Failure and is currently suspended. Martin Pharmaceuticals leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Suspended PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Suspended PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1
-
Apr 2021 — Jul 2024 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
▶ Show 9 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Jun 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE1
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Martin Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerp, Belgium , Barcelona, Spain , Brussels, Belgium , Córdoba, Spain , Essen, Germany , Frankfurt, Germany , Graz, Austria , Halle, Germany , Hanover, Germany , Heidelberg, Germany and 11 more locations